Literature DB >> 25293769

PARP-14 combines with tristetraprolin in the selective posttranscriptional control of macrophage tissue factor expression.

M Bilal Iqbal1, Michael Johns1, Jun Cao1, Yu Liu1, Sheng-Chun Yu1, Gareth D Hyde1, Michael A Laffan2, Francesco P Marchese3, Sung Hoon Cho4, Andrew R Clark5, Felicity N Gavins2, Kevin J Woollard2, Perry J Blackshear6, Nigel Mackman7, Jonathan L Dean3, Mark Boothby4, Dorian O Haskard1.   

Abstract

Tissue factor (TF) (CD142) is a 47 kDa transmembrane cell surface glycoprotein that triggers the extrinsic coagulation cascade and links thrombosis with inflammation. Although macrophage TF expression is known to be regulated at the RNA level, very little is known about the mechanisms involved. Poly(adenosine 5'-diphosphate [ADP]-ribose)-polymerase (PARP)-14 belongs to a family of intracellular proteins that generate ADP-ribose posttranslational adducts. Functional screening of PARP-14-deficient macrophages mice revealed that PARP-14 deficiency leads to increased TF expression and functional activity in macrophages after challenge with bacterial lipopolysaccharide. This was related to an increase in TF messenger RNA (mRNA) stability. Ribonucleoprotein complex immunoprecipitation and biotinylated RNA pull-down assays demonstrated that PARP-14 forms a complex with the mRNA-destabilizing protein tristetraprolin (TTP) and a conserved adenylate-uridylate-rich element in the TF mRNA 3' untranslated region. TF mRNA regulation by PARP-14 was selective, as tumor necrosis factor (TNF)α mRNA, which is also regulated by TTP, was not altered in PARP-14 deficient macrophages. Consistent with the in vitro data, TF expression and TF activity, but not TNFα expression, were increased in Parp14(-/-) mice in vivo. Our study provides a novel mechanism for the posttranscriptional regulation of TF expression, indicating that this is selectively regulated by PARP-14.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25293769      PMCID: PMC4256914          DOI: 10.1182/blood-2014-07-588046

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Phosphorylation of tristetraprolin by MK2 impairs AU-rich element mRNA decay by preventing deadenylase recruitment.

Authors:  Sandra L Clement; Claudia Scheckel; Georg Stoecklin; Jens Lykke-Andersen
Journal:  Mol Cell Biol       Date:  2010-11-15       Impact factor: 4.272

Review 2.  RNA regulons: coordination of post-transcriptional events.

Authors:  Jack D Keene
Journal:  Nat Rev Genet       Date:  2007-07       Impact factor: 53.242

3.  MAPKAP kinase 2 blocks tristetraprolin-directed mRNA decay by inhibiting CAF1 deadenylase recruitment.

Authors:  Francesco P Marchese; Anna Aubareda; Corina Tudor; Jeremy Saklatvala; Andrew R Clark; Jonathan L E Dean
Journal:  J Biol Chem       Date:  2010-07-01       Impact factor: 5.157

Review 4.  New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs.

Authors:  Bryan A Gibson; W Lee Kraus
Journal:  Nat Rev Mol Cell Biol       Date:  2012-06-20       Impact factor: 94.444

5.  PARP-14 functions as a transcriptional switch for Stat6-dependent gene activation.

Authors:  Purvi Mehrotra; Jonathan P Riley; Ravi Patel; Fang Li; Le'erin Voss; Shreevrat Goenka
Journal:  J Biol Chem       Date:  2010-11-16       Impact factor: 5.157

6.  Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability.

Authors:  K R Mahtani; M Brook; J L Dean; G Sully; J Saklatvala; A R Clark
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

7.  Interactions of CCCH zinc finger proteins with mRNA. Binding of tristetraprolin-related zinc finger proteins to Au-rich elements and destabilization of mRNA.

Authors:  W S Lai; E Carballo; J M Thorn; E A Kennington; P J Blackshear
Journal:  J Biol Chem       Date:  2000-06-09       Impact factor: 5.157

8.  The RNA-binding zinc-finger protein tristetraprolin regulates AU-rich mRNAs involved in breast cancer-related processes.

Authors:  N Al-Souhibani; W Al-Ahmadi; J E Hesketh; P J Blackshear; K S A Khabar
Journal:  Oncogene       Date:  2010-05-24       Impact factor: 9.867

9.  Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque.

Authors:  J N Wilcox; K M Smith; S M Schwartz; D Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

10.  Tissue factor mRNA in THP-1 monocytic cells is regulated at both transcriptional and posttranscriptional levels in response to lipopolysaccharide.

Authors:  K Brand; B J Fowler; T S Edgington; N Mackman
Journal:  Mol Cell Biol       Date:  1991-09       Impact factor: 4.272

View more
  24 in total

Review 1.  ADP-ribosyltransferases and poly ADP-ribosylation.

Authors:  Chao Liu; Xiaochun Yu
Journal:  Curr Protein Pept Sci       Date:  2015       Impact factor: 3.272

2.  PARP14 inhibits microglial activation via LPAR5 to promote post-stroke functional recovery.

Authors:  Ying Tang; Jinchang Liu; Yu Wang; Li Yang; Bing Han; Yuan Zhang; Ying Bai; Ling Shen; Mingyue Li; Teng Jiang; Qingqing Ye; Xiaoyu Yu; Rongrong Huang; Zhao Zhang; Yungen Xu; Honghong Yao
Journal:  Autophagy       Date:  2020-12-15       Impact factor: 16.016

3.  A Stat1 bound enhancer promotes Nampt expression and function within tumor associated macrophages.

Authors:  Thomas B Huffaker; H Atakan Ekiz; Cindy Barba; Soh-Hyun Lee; Marah C Runtsch; Morgan C Nelson; Kaylyn M Bauer; William W Tang; Timothy L Mosbruger; James E Cox; June L Round; Warren P Voth; Ryan M O'Connell
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

4.  Dominant Suppression of Inflammation via Targeted Mutation of the mRNA Destabilizing Protein Tristetraprolin.

Authors:  Ewan A Ross; Tim Smallie; Qize Ding; John D O'Neil; Helen E Cunliffe; Tina Tang; Dalya R Rosner; Iva Klevernic; Nicholas A Morrice; Claudia Monaco; Adam F Cunningham; Christopher D Buckley; Jeremy Saklatvala; Jonathan L Dean; Andrew R Clark
Journal:  J Immunol       Date:  2015-05-22       Impact factor: 5.422

5.  Δ(9)-Tetrahydrocannabinol (THC) enhances lipopolysaccharide-stimulated tissue factor in human monocytes and monocyte-derived microvesicles.

Authors:  Julie C Williams; Thomas W Klein; Bruce A Goldberger; John W Sleasman; Nigel Mackman; Maureen M Goodenow
Journal:  J Inflamm (Lond)       Date:  2015-06-12       Impact factor: 4.981

Review 6.  RNA Regulation by Poly(ADP-Ribose) Polymerases.

Authors:  Florian J Bock; Tanya T Todorova; Paul Chang
Journal:  Mol Cell       Date:  2015-06-18       Impact factor: 17.970

7.  PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation.

Authors:  Hiroshi Iwata; Claudia Goettsch; Amitabh Sharma; Piero Ricchiuto; Wilson Wen Bin Goh; Arda Halu; Iwao Yamada; Hideo Yoshida; Takuya Hara; Mei Wei; Noriyuki Inoue; Daiju Fukuda; Alexander Mojcher; Peter C Mattson; Albert-László Barabási; Mark Boothby; Elena Aikawa; Sasha A Singh; Masanori Aikawa
Journal:  Nat Commun       Date:  2016-10-31       Impact factor: 14.919

8.  Effect of ATRA and ATO on the expression of tissue factor in NB4 acute promyelocytic leukemia cells and regulatory function of the inflammatory cytokines TNF and IL-1β.

Authors:  Sylvie Dunoyer-Geindre; Anne-Sophie Rivier-Cordey; Olga Tsopra; Thomas Lecompte; Egbert K O Kruithof
Journal:  Ann Hematol       Date:  2017-03-25       Impact factor: 3.673

9.  PARP14 regulates cyclin D1 expression to promote cell-cycle progression.

Authors:  Michael J O'Connor; Tanay Thakar; Claudia M Nicolae; George-Lucian Moldovan
Journal:  Oncogene       Date:  2021-06-22       Impact factor: 9.867

10.  A low balance between microparticles expressing tissue factor pathway inhibitor and tissue factor is associated with thrombosis in Behçet's Syndrome.

Authors:  E Khan; N L Ambrose; J Ahnström; A P Kiprianos; M R Stanford; D Eleftheriou; P A Brogan; J C Mason; M Johns; M A Laffan; D O Haskard
Journal:  Sci Rep       Date:  2016-12-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.